Background/Objectives: Psoriasis is a chronic immune-mediated skin disease associated with several metabolic comorbidities. Metabolic dysfunction-associated steatotic liver disease (MASLD) is also linked to psoriasis, but evidence regarding the severity of this association remains inconclusive. This meta-analysis aimed to investigate the relationship between MASLD and varying severities of psoriasis. Methods: We conducted an extensive search of four databases, MEDLINE, EMBASE, OSF, and ClinicalTrials.gov to identify relevant published articles assessing the risk of prevalent MASLD in patients with moderate-to-severe psoriasis up to April 2024. Effect estimates from each included study were combined together to calculate a pooled effect estimate for the meta-analysis using the generic inverse variance method of DerSimonian and Laird. Results: This meta-analysis included eight studies with a total of 109,806 participants. A 4.01-fold increased risk of prevalent MASLD was observed in patients with moderate-to-severe psoriasis compared to those without psoriasis (95% CI: 2.17, 7.77; I² = 67%, p < 0.0001). The evidence supporting this outcome had low certainty. Conclusions: An incremental trend of MASLD was observed in patients with moderate-to-severe psoriasis. Routine screening for MASLD should be emphasized in this population.

Introduction: Infertility, a global concern affecting both sexes, is influenced by modifiable and non-modifiable risk factors. While the literature predominantly underscores the clinical- and cost-effectiveness of lifestyle interventions in the realm of infertility treatment, a holistic compilation analysing the economic dimensions of such interventions is lacking. This systematic review aimed to fill this gap by evaluating the economic facets of lifestyle interventions in the management of infertility.Methods: An exhaustive search was conducted within the PubMed, Embase, and Scopus databases from their inception to February 2024. The aim was to find articles related to the economic aspects of lifestyle interventions in infertility management. These included clinical studies covering economic outcomes and economic evaluations. The Drummond Checklist was used to assess the quality of the included studies.Results: From an initial yield of 7555 articles, five studies were deemed eligible for inclusion, comprising three cost-effectiveness analyses, one prospective cohort study and a randomized controlled trial, all of which were undertaken in high-income countries (the Netherlands, Australia and Japan). These studies included patients receiving infertility treatments for conditions such as unexplained infertility, polycystic ovary syndrome, ovulation disorders, or mild male infertility, inclusive of individuals with and without obesity. The women who participated in these studies were up to 45 years of age. The findings suggested that integrating lifestyle intervention programmes tends to enhance pregnancy and live birth outcomes. These programmes encompass coaching, psychological or behavioural guidance, nutritional adjustments, exercise regimes, weight management, smoking cessation and mindfulness techniques. Moreover, these interventions are likely to be more cost-effective than standard infertility care.Conclusion: For couples embarking on infertility treatments, the integration of lifestyle interventions into their management strategy not only fosters clinical benefits but also represents a cost-effective alternative to conventional care, particularly within high-income settings.

Background/Objective: Lichen sclerosus is a chronic inflammatory skin disease that affects people of all ages and sexes. Evidence of cardiovascular risk factors in lichen sclerosus has been continuously reported; however, the definitive association remains inconclusive. This meta-analysis aimed to summarize the association between cardiovascular risk factors and lichen sclerosus. Methods: Electronic databases, including MEDLINE and EMBASE, were systematically searched from inception to May 2024 to identify the literature reporting the association between cardiovascular risk factors and lichen sclerosus. A random-effects model was used for the meta-analysis. Results: We included 16 eligible studies: nine case–control studies, six retrospective cohort studies, and one cross-sectional study. A total of 432,457 participants were included. Lichen sclerosus was significantly associated with type 2 diabetes mellitus with an odds ratio of 2.07 (95% CI: 1.21–3.52). Although not statistically significant, a trend of increasing risk in hypertension, dyslipidemia, obesity, and metabolic syndrome was observed among lichen sclerosus patients, with odds ratios of 1.56 (95% CI: 0.90–2.70), 1.44 (95% CI: 0.94–2.23), 5.84 (95% CI: 0.37–92.27), and 1.36 (95% CI: 0.52–3.54), respectively. Conclusions: Lichen sclerosus was associated with diabetes mellitus and potentially correlated with hypertension, dyslipidemia, obesity, and metabolic syndrome. Population-based prospective observational studies are required to further elucidate these findings and assess the impact of these associations.

INPLASY202510068 The Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease in Moderate-to-Severe Psoriasis: A systematic review and meta-analysis Psoriasis; meta-analysis; liver disease;…

Lichen sclerosus (LS) is a chronic inflammatory skin disease affecting both genital and extra-genital areas and is found predominantly in female patients. The relationship between LS and thyroid diseases remains unclear, with conflicting evidence reported in the literature. This systematic review and meta-analysis aimed to investigate the association between LS and thyroid diseases rigorously. We conducted a comprehensive search using two electronic databases, MEDLINE and Embase, from inception to May 2024, to identify observational studies investigating the relationship between LS and thyroid diseases. A random-effects model was used to meta-analyse the pooled odds ratio with a 95% confidence interval (CI) from the included articles. A total of 14 observational articles encompassing 22,112,979 participants were included. Nine of these studies included only female participants. The analysis revealed that LS was significantly associated with an increased risk of autoimmune thyroid diseases, with an odds ratio of 2.38 (95% CI, 1.46-3.86; I² = 84%). Additionally, an association was found between hyperthyroidism and an odds ratio of 2.01 (95% CI, 1.40-2.88; I² = 0%). Furthermore, patients with LS exhibited a non-significant increase in the odds ratio for Graves' disease, Hashimoto's thyroiditis, hypothyroidism and other unspecified thyroid disorders. This meta-analysis provided insight into thyroid diseases in patients with LS, revealing a significant association with an increased risk of autoimmune thyroid disease and hyperthyroidism. Further research is needed to clarify this association and enhance the comprehensive care of patients with LS.

Basal cell carcinoma (BCC) is the most common form of skin cancer and poses treatment challenges in advanced stages. Treatment options include surgery, radiotherapy, and systemic therapies, but tumor location and prior interventions can limit these methods. Hedgehog pathway inhibitors (HPIs) are used for patients unsuitable for conventional treatments. This meta-analysis evaluated the effectiveness and safety profile of HPIs in managing advanced BCC. We conducted a comprehensive literature review across Embase, Scopus, PubMed, and the Cochrane Central Register of Controlled Trials databases from inception until March 2024. The focus was on the effectiveness and safety of HPIs, with or without adjunct surgery or radiotherapy. Pooled objective response rates (ORRs) and 95% confidence intervals (CIs) were calculated using inverse variance random-effects models. The analysis comprised 16 studies, including 14 retrospective cohort studies, one prospective cohort study, and one randomized controlled trial, with 1689 participants. The pooled ORR for HPIs was 73% (95% CI 63%–82%; I² = 93%) across all stages of the disease. For locally advanced disease, the ORR was 63% (95% CI 49%–75%; I² = 89%), while for metastatic disease, it was 25% (95% CI 14%–40%; I² = 19%). No significant differences were found in the effectiveness of different HPIs. ORRs ranged from 25% to 89% for patients who underwent surgery or radiotherapy. This meta-analysis indicates that HPIs are more beneficial in treating locally advanced BCC than metastatic disease. No statistically significant differences were found in the effectiveness among various HPIs.